scispace - formally typeset
R

Rolf Jaussi

Researcher at Paul Scherrer Institute

Publications -  46
Citations -  2084

Rolf Jaussi is an academic researcher from Paul Scherrer Institute. The author has contributed to research in topics: Phage display & Signal transduction. The author has an hindex of 25, co-authored 46 publications receiving 1907 citations.

Papers
More filters
Journal ArticleDOI

Structure-function relationship of CAP-Gly domains

TL;DR: The findings define the molecular basis of CAP-Gly domain function, including the tubulin detyrosination-tyrosination cycle, and establish fundamental roles for the interaction between CAP-gly proteins and C-terminal EEY/F sequence motifs in regulating complex and dynamic cellular processes.
Journal ArticleDOI

Structural basis of tubulin tyrosination by tubulin tyrosine ligase

TL;DR: Structural analysis of a complex of tubulin and tubulin tyrosine ligase (TTL) reveals insights into TTL’s enzymatic mechanism, how it discriminates between α- and β-tubulin, and its possible evolutionary origin.
Journal ArticleDOI

Key Interaction Modes of Dynamic +TIP Networks

TL;DR: These findings provide a molecular basis for understanding the modular interaction modes between alpha-tubulin, CLIPs, EB proteins, and the dynactin-dynein motor complex and suggest that multiple low-affinity binding sites in different combinations control dynamic +TIP networks at microtubule ends.
Journal ArticleDOI

Display of expression products of cDNA libraries on phage surfaces. A versatile screening system for selective isolation of genes by specific gene-product/ligand interaction.

TL;DR: The developed cloning strategy allows isolation of cDNAs encoding proteins for which a ligand is available and circumvents immobilisation of the libraries on solid-phase supports which hamper selective enrichment of clones expressing the desired protein.
Journal ArticleDOI

Structural basis for recognition of synaptic vesicle protein 2C by botulinum neurotoxin A

TL;DR: The high-resolution crystal structure of the BoNT/A receptor-binding domain (BoNT/ a-RBD) in complex with the SV2C luminal domain (SV2C-LD) is determined, providing a strong platform for the development of novel antitoxin agents and for the rational design of Bo NT/A variants with improved therapeutic properties.